Patient tumor cells

Patient tumor cells are the fundamental biological units of malignancy, characterized by genomic instability, uncontrolled proliferation, and the ability to evade programmed cell death (Hanahan & Weinberg, 2011). While not a discrete molecular target such as a single receptor or enzyme, these cells represent the primary pathological entity that oncology therapeutics aim to eliminate or control. In the field of precision medicine, patient-derived tumor cells are increasingly used in functional assays to predict individual drug sensitivities and resistance patterns, bridging the gap between genomic data and clinical outcomes (Letai, 2017). These cells exist within a complex tumor microenvironment that influences their behavior and response to therapy, often presenting significant challenges such as physical barriers to drug delivery and immune suppression (Fisher et al., 2013). Because tumor cells are highly heterogeneous, targeting them effectively requires a combination of cytotoxic agents, targeted molecular therapies, and immunotherapies tailored to the specific characteristics of the patient's disease.

Other names

Cancer cellsMalignant cellsNeoplastic cellsPatient-derived tumor cellsPDCsTumor-derived cells

Drugs interact with patient tumor cells through diverse mechanisms including the induction of DNA damage, inhibition of essential survival signaling pathways (e.g., tyrosine kinase inhibition), and the modulation of the immune system to facilitate cell-mediated cytotoxicity (National Cancer Institute, 2023).